Oncology
Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer
April 9, 2026Oncology
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the updated prescribing information for Daiichi Sankyo’s Enhertu (trastuzumab), a …
Outrun Therapeutics announces its lead programme for HPV positive cancer
March 23, 2026Research and Development HPV, Oncology, Outrun Therapeutics
Outrun Therapeutics has selected an E6AP inhibitor strategy as its lead programme for treating HPV positive head and neck cancer. …
Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine
February 11, 2026Research and Development Infinitopes, Oncology
Infinitopes, a clinical stage biotechnology company specialising in oncology, has announced the receipt of an additional $15.4m in seed funding, …
QV Bioelectronics secures £4.5m in funding for brain cancer therapy development
February 3, 2026Research and Development Oncology, QV Bioelectronics, glioblastoma
QV Bioelectronics, a medtech business specialising in implants for cancer treatment, has announced that it has received £4.5m in funding …
Pierre Fabre Laboratories and Iktos announce oncology collaboration
January 21, 2026Research and Development Iktos, Oncology, Pierre Fabre Laboratories
Pierre Fabre Laboratories and Iktos have announced a new collaboration intended to discover and develop new small-molecule drug candidates for …
Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
January 14, 2026Research and Development Bio-Sourcing, Oncology, Zerion Pharma, breast cancer
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of the monoclonal antibody trastuzumab for …
Biocartis announces breast cancer research collaboration with US Mayo Clinic
January 14, 2026Research and Development Biocartis, Mayo Clinic, Oncology, breast cancer
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop an accelerated sample-to-answer test resulting …
Blue Earth announces first UK patient received prostate cancer injection
January 13, 2026Research and Development Blue Earth Therapeutics, Oncology, prostate cancer
Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first UK patient has received its …
Breast Cancer Now study to explore personalised drug doses
December 9, 2025Research and Development Breast Cancer Now, Oncology
Breast Cancer Now has announced a new study to evaluate whether personalised drug doses could improve quality of life for …
Samsung Bioepis announces launch of two new denosumab biosimilars in Europe
December 4, 2025Sales and Marketing Oncology, Osteoporosis, Samsung Bioepis
Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars approved for the treatment of …
Sandoz launches two new bone disease biosimilars in Europe
December 3, 2025Sales and Marketing Oncology, Osteoporosis, Sandoz
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 mg) is approved for the …
Medicus Pharma shares updates on basal cell carcinoma trials
December 2, 2025Research and Development Medicus Pharma, Oncology
Medicus Pharma has announced updates on the progress of SKNJCT-003 and SKNJCT-004, its clinical trials studying the efficacy of a …
One-carbon Therapeutics starts new cancer therapy trial
November 27, 2025Research and Development Oncology, One-carbon Therapeutics
Clinical-stage biotechnology company One-carbon Therapeutics has announced that the first subject has been dosed in its clinical trial for TH9619, …
Accession Therapeutics doses first patient in new cancer immunotherapy trial
November 26, 2025Research and Development Accession Therapeutics, Oncology
Biopharmaceutical company Accession Therapeutics has announced the dosing of the first patient in the phase 1 clinical trial of TROCEPT-01 …
ViVac Pharma appoints Keren Leshem as CEO
November 26, 2025CEO, Oncology, ViVac Pharma
Early-stage biotechnology company ViVac Pharma has appointed Keren Leshem as its new CEO. Leshem brings almost 30 years of experience …
Latest content
FibroFind appoints Lee Borthwick as CEO
